EUVIMEDEUVIMED entdecken
Crossref

Clinical Utility of Virtual Crossmatch Reliability in Living Donor Kidney Transplantation

Naoya Iwahara iD, Kiyohiko Hotta iD, Takayuki Hirose iD, Makoto Ito, Hiroki Hashiguchi, Takashige Abe iD

Nephrology · 2026-11 · 31 (11)

DOI: 10.1111/nep.70309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology, online erschienen am 06.11.2026. Verfasst von Naoya Iwahara und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal and Genitourinary Surgery, Faculty of Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Kidney Transplantation, Living Donors, Graft Rejection, Isoantibodies. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Donor‐specific antibodies (DSA) are associated with antibody‐mediated rejection (AMR) and graft loss in kidney transplantation. In deceased donor kidney transplantation, virtual crossmatch (VXM) using solid‐phase assays has largely replaced physical crossmatch (PXM). However, comparative data in living donor kidney transplantation (LDKT), particularly for Japanese recipients, remain limited. This study examined the correlation between VXM and PXM and evaluated the incidence of early AMR in Japanese LDKT. We retrospectively analysed 102 LDKT recipients between July 2012 and August 2020, all of whom underwent both VXM and PXM. Patients were stratified into four groups: VXM+/PXM+, VXM+/PXM−, VXM−/PXM+, and VXM−/PXM−. Discordant results were observed in 7% of cases. VXM+/PXM− cases involved low‐titre DSA undetectable by flow cytometric crossmatch (FCXM), whereas all VXM−/PXM+ cases were B‐cell FCXM‐positive in ABO‐incompatible recipients. In ABO‐compatible transplantation, AMR developed in 43% (3/7) of VXM+/PXM+ recipients, 0% (0/1) of VXM+/PXM−, and 2% (1/57) of VXM−/PXM− recipients; no VXM−/PXM+ cases were observed. The VXM+/PXM+ group demonstrated frequent severe AMR, with two cases progressing to chronic active AMR. In contrast, AMR in the VXM−/PXM− group was rare, mild, and successfully managed with steroid pulse therapy alone. These findings indicate that VXM provides reliable immunologic risk stratification in Japanese LDKT and can serve as a practical alternative to PXM without compromising clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationLiving DonorsGraft RejectionIsoantibodiesHistocompatibility TestingBlood Grouping and CrossmatchingHumansRetrospective StudiesFemaleMaleMiddle AgedAdultReproducibility of ResultsJapanGraft Survival

Stichwörter der Autor:innen

Japanese recipientsantibody‐mediated rejectiondonor‐specific antibodyphysical crossmatchvirtual crossmatch

Substanzen

Isoantibodies

Autor:innen und Institutionen

  • Department of Renal and Genitourinary Surgery, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan.
  • Clinical Laboratory, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.

ORCID-Profile: Naoya Iwahara, Kiyohiko Hotta, Takayuki Hirose, Takashige Abe

Zitieren

APA

Iwahara, N., Hotta, K., Hirose, T., Ito, M., Hashiguchi, H., & Abe, T. (2026). Clinical Utility of Virtual Crossmatch Reliability in Living Donor Kidney Transplantation. Nephrology, 31(11). https://doi.org/10.1111/nep.70309

Vancouver

Iwahara N, Hotta K, Hirose T, Ito M, Hashiguchi H, Abe T. Clinical Utility of Virtual Crossmatch Reliability in Living Donor Kidney Transplantation. Nephrology. 2026;31(11). doi:10.1111/nep.70309

BibTeX
@article{Iwahara2026,
  author = {Iwahara, Naoya and Hotta, Kiyohiko and Hirose, Takayuki and Ito, Makoto and Hashiguchi, Hiroki and Abe, Takashige},
  title = {Clinical Utility of Virtual Crossmatch Reliability in Living Donor Kidney Transplantation},
  journal = {Nephrology},
  year = {2026},
  volume = {31},
  number = {11},
  doi = {10.1111/nep.70309}
}
Kostenlos starten →